FDA upholds decision on generic version of GSK’s asthma/COPD inhaler Advair Diskus

This article was originally published here

The US Food and Drug Administration (FDA) has upheld the earlier decision of turning down Hikma and Vectura’s generic version of GlaxoSmithKline’s (GSK) Advair Diskus (fluticasone propionate and salmeterol inhalation powder).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply